

# Discussion on Strategy

Comments

# Key points

- ANDI's role is facilitatory – finalisation of document should be clear on this, so that expectations are clear
- Need regional/subregional and thematic subnetworks to operationalise CoEs and Hubs
- Various co-financing models need to be explored
- Co-sharing of facilities and staff needs to be facilitated within the limits ethics and other dimensions
- Information management is key, and the necessary capacity is required at secretariat level
- Local-local and South-South collaborations should be facilitated
- Need a list of priority products and technologies to focus on (low-hanging fruits)
- Brokerage events are an important opportunity to tap on
- Need clarification on engagement of pharmaceutical companies

# Details to consider in implementation

- For effective networking ... e.g. schisto network (CoE) ... have clusters for different research disciplines (med chem, mol boil, toxicity etc) around this issue ... at continental level ... similar to a FP7 funded project. Would be good for collaboration and sustainability
- South-South collaboration ... ANDI should focus more on stimulating these. Egypt has competence in immunodiagnostics ... which can be leverage. ANDI can have agreements with local funding agencies (to pursue to example of Egypt with Amr). Covering capacity building as well
- What kind of arrangement would be needed e.g. MoUs ... given the different scales of operation? It would be easier for local networks

# Details to consider in implementation

- Egypt has existing funding and institutional mechanisms already for such networks ... experiences to be shared. ANDI can facilitate this
- Details will also be tailored to specific thematic
- Extent to which ANDI will engage pharmaceutical industry ... at what stage and how?
- CoE thought they were going to receive funding ... it wasn't clear ANDI were only going to facilitate. ANDI can/should prepare a plan for in-kind assistance ... e.g. facilitating links with donors, funders, suppliers
- ANDI did increase visibility of individual researchers and scientists
- ANDI is now much more focused ... message of focus needs to be communicated
- Two way process ... but ANDI should play a key role in horizon scanning

# Implementation

- BVGH experience ... looking for different organisations that can help on behalf of their members (e.g. equipment from Stanford) ... there are different ways to achieve this ... no single formula
- ANDI co-facilities ... raising economies of scale. Would make sure equipment is utilised optimally (e.g. bioanalysis and immunodiagnosics) ... taking on board ethics and sensitivities around moving samples. Is happening already, mainly with European/northern partners ... issue is mainly political ... ANDI could facilitate
- Sharing experiences and knowing who is doing what to avoid replication of studies. Thematic areas and databases will be helpful

# Brokerage

- Events should be made effective, with a lot of effort and planning
- What do we know about the appetite of funders for brokerage activities
- Sub networks can be built around the hubs
- Sub-networks around hubs will help in coordination
- Technical input and catalytic funding ... this needs to be clarified to avoid
- Can technical input mean input on process of innovation or on the technology directly ... it's about facilitation or knowledge sharing
- ANDI will establish partnerships ... no ... facilitate establishment of partnerships

# Financing

- Co-financing models ... an emerging trend ... can these be explored ... and experiences shared between countries
- Euro-mediterranean area experience ... bringing together international funding, NGO funding and government level funding .. Industry also coming into the partnerships
- ANDI can group partners, facilitate priority setting to then set up the models
- ANDI can look at different models ... e.g. the Japan Global Health Investment fund ... with Gates, Japanese companies and govt ... and see what fits into the ANDI objectives. Maybe this could get African govts interested in funding, and this would in turn interest other funders like Gates

# Financing

- Co-financing ... depends on how you approach the government ... ANDI should prioritise and identify promising research which can be used to entice governments ... show cause or value added
- Need for indicators
- Systems for procurement ... need for standardisation
- Open up and allow competition to shape the processes
- Drugs ... follow EDLs ... documentation of process by WB. Evaluation and accountability
- Role for ANDI ... facilitate use of competitive processes
- ANDI ... facilitate research partnerships ... minimal on procurement
- No need to focus on clinical trials ... facilitate links to other who do that best e.g. EDCTP ... but there are some overlaps which should be thought through and leveraged
- Is there a range of health products being focused on? This would be a good idea. Given the strengths of ANDI.
- ANDI should be clear about a list of low-hanging fruits ... after mapping all innovations

# Information management platform

- Is there expertise in ANDI to set up and manage these platforms?
- There is also a list of tasks under this function
- The challenge of information sharing in phyto-medicines
- Keeping platform up to date, facilitate knowledge sharing